Kalaris is a clinical stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases with major unmet medical needs, focusing on TH103, a novel anti-VEGF drug
Kalaris is a clinical stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases with major unmet medical needs, focusing on TH103, a novel anti-VEGF drug.
The top three firms on F4's Biotech & Life Sciences investor list.